Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2018-04-05 | Donald M. Abbey Mr. Abbey, 51, has been director since January 2018. |
| 2019-04-05 | Mr. Abbey, 52, has been director since January 2018 and is a member of the Nominating Governance Committee and the Compensation Committee. |
| 2020-04-03 | Donald M. Abbey, member of Nominating Governance Committee and Compensation Committee, 2019 total compensation $240,014. |
| 2021-04-01 | Donald M. Abbey Mr. Abbey, 54, has been director since January 2018 and is a member of the Nominating Governance Committee and the Compensation Committee. |
| 2022-04-04 | Mr. Abbey, 55, has been a director since January 2018 and is a member of the Nominating Governance Committee and the Compensation Committee. Mr. Abbey is currently serving as Executive Vice President, Global Business Services, IT, Quality and Regulatory Affairs at Dexcom, Inc. (“Dexcom”). Mr. Abbey joined Dexcom in May of 2016. Prior to joining Dexcom, Mr. Abbey was with Becton Dickinson (who acquired CareFusion Corporation in 2015 and which was spun out of Cardinal Health in 2009 (collectively, “BD”) from 2007. Mr. Abbey served in many roles over his years at BD including most recently as the Senior Vice President, Quality and Regulatory. Prior to his time at BD, Mr. Abbey held senior quality and regulatory affairs and general management positions with Respironics, Welch Allyn and Philips Healthcare. Mr. Abbey began his career at Varian Medical and Boston Scientific holding positions with increasing responsibility in research and development and quality. Mr. Abbey received a B.S.E.E from Washington State University and a M.B.A from University of Washington.The Board believes Mr. Abbey should serve as a director due to his extensive knowledge and experience in the medical industry and particularly, his knowledge of compliance and regulatory requirements. |
| 2023-04-04 | Mr. Abbey, 56, has been a director since January 2018 and is a member of the Nominating Committee and the Compensation Committee. ... The Board has determined that directors Messrs. Greenberg, Abbey, and Hoffmeister, Ms. Finney, Ms. Hernandez and Ms. Kennedy qualify as independent under NASDAQ Listing Rules. |
| 2024-04-02 | Mr. Abbey, 57, has been a director since January 2018 and is a member of the Nominating Committee and the Compensation Committee. ... The Board believes Mr. Abbey should serve as a director due to his extensive knowledge and experience in the medical industry and particularly, his knowledge of compliance and regulatory requirements. |
| 2025-04-03 | Mr. Abbey, 58, has been a director since January 2018 and is a member of the Nominating Committee and the Compensation Committee. ... The Board believes Mr. Abbey should serve as a director due to his extensive knowledge and experience in the medical industry and particularly, his knowledge of compliance and regulatory requirements. |
Data sourced from SEC filings. Last updated: 2026-02-03